ReeLabs is a zero debt, presently 10 crore company with a working capital of 100 crores that has recently
ventured into cord blood banking and stem cell research and therapy.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Encryption in Microsoft 365 - ExpertsLive Netherlands 2024Albert Hoitingh
In this session I delve into the encryption technology used in Microsoft 365 and Microsoft Purview. Including the concepts of Customer Key and Double Key Encryption.
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
2. This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced
Cell Technology Inc”, or “the Company”) salient business characteristics.
The information herein contains “forward-looking statements” as defined under the
federal securities laws. Actual results could vary materially. Factors that could cause
actual results to vary materially are described in our filings with the Securities and
Exchange Commission.
You should pay particular attention to the “risk factors” contained in documents we
file from time to time with the Securities and Exchange Commission. The risks
identified therein, as well as others not identified by the Company, could cause the
Company’s actual results to differ materially from those expressed in any forward-
looking statements.
Cautionary Statement Concerning Forward-Looking
Statements
2
3. State of the Company
• Phase I/II ESC trial fully-funded (and not
affected by court ruling) and awaiting FDA
approval
• “Embryo-safe” cell lines may qualify for
federal funding, despite recent court ruling
• Actively pursuing alternatives to
accelerate development of programs
3
4. ACT Therapeutics
ACT Proprietary Human
Therapeutic Programs
Treatment Clinical Stage
Blastomere Program
Development of embryonic stem cell lines without
destruction of embryo
Pre-Clinical
Retinal Pigment Epithelium
(RPE) Program
Treatment of Age-related Macular Degeneration
(AMD) and Retinal Degenerative Diseases
Clinical IND
awaiting
FDA approval
Myoblast Program
Treatment of Heart Disease, Heart Attack and
Heart Failure
Phase II
Hemangioblast program
Treatment of Diseases and Disorders of the
Blood, Circulatory and Vascular Systems
Pre-Clinical
4
5. Single Blastomere Technology
• Company scientists successfully generate stem cell lines
without destruction of embryo
• Utilizes PGD extraction of single blastomere
• PGD is safe and routine – has been used in thousands of
pregnancies in United States and Europe alone.
• Cell lines retain potential to form all cells in the human body.
• Resulting human ES cell lines have been demonstrated to be
more robust and reproducible than traditional ICM-derived
lines.
• Technology has been reproduced and peer-reviewed on
several occasions, and is currently being used in preclinical
studies and a product awaiting FDA approval for IND study.
5
Blastomere Program:
hESCs Without Embryo Harm
6. • Enables Derivation of New hESC Lines via Pre-
implantation Genetic Diagnosis (PGD) Method,
Preserving Development Potential of the Embryo
• Offers source of autologous ES cells for donor
during his/her life, and closely matched allogeneic
source for blood relatives.
• 4 hESC lines awaiting NIH approval for funding – embryos
from which these lines were derived were not destroyed.
• Technology is used to develop RPE cells for our clinical
trials for Juvenile Macular Degeneration. (no Federal
Funding)
• Technology is used to develop Hemangioblasts –
potential source for red blood cells and platelets.
Hemangioblasts
Differentiated from
Blastomere hESC Lines
6
Blastomere Program:
Proven Alternative hESC Method with added Benefits
7. • The Sherley v. Sebelius case presents a major challenge
for the regenerative medicine sector, without a doubt.
• However, ACT has anticipated this development for
some time
• ACT has been taking high-level, face-to-face meetings in
DC with all the relevant players, in both houses and on
both sides of the aisle, as well as with NIH and HHS.
• ACT‟s Single Blastomere technique for isolating
hESC‟s is likely not subject to the language Judge
Lamberth used in Preliminary Injunction.
• ACT stands ready to make these cells available to
the research community, if approved.
7
With Crisis, Comes Opportunity
Current Challenge to hESC Federal Funding
8. Institutional Collaborators
Advanced Cell’s Institutional Collaborators include:
Casey Eye Institute Mayo Clinic
Moran Eye Institute UCSF
Harvard Johns Hopkins
Stanford Sloan Kettering
University of Florida University of Iowa
University of Illinois U.C. Berkeley
Colorado State University
8
9. Robust Patent Portfolio
• RPE Program
• Broad protection for production of RPE cells from human ES Cells
• Includes two issued US Patents
• Cover use of hESC-dervied RPE cells for treatment of retinal
degenerative disorders
• Single Blastomere
• Pending patent application for key technology
• Induced Pluripotency (iPS)
• ACT has earliest priority date to use of key regulatory factors required for
generating iPS cells.
• Transdifferentiation
• Broad filings directed to transdifferentiation without viral vectors
• SCNT
• Dominant issued patents
• Parthenogenesis
• Aquired Infigen patents which are controlling in parthenogenesis
9
Realizing the fruits of more than a
decade of important discoveries….
10. RPE Program: Why RPE?
• Pigmented epithelium cells are easy to identify
• Small dosage vs. other therapies
• The eye is an immune-privileged site, thus no risk
of rejection at the injection site
• Ease of administration
– Doesn‟t require a separate approval by the FDA (universal applicator)
– Procedure is already used by eye surgeons; no new skill set required
for doctors
• RPE cell therapy may positively impact over 200 retinal diseases
10
11. ACT’s RPE Program IND - Status
• Received Orphan Indication
• Application for Phase I/II Trial Being
Reviewed
11
• Initial IND for Stargardt’s Disease
• Trial Design Dovetails Into Second IND, for Dry AMD
• Represents $25-30 Billion Worldwide Market, With No
Effective Therapies Currently Available
12. Myoblast Program Highlights
Target Market for Myoblast Program
Sufferers of Heart Failure, Chronic Heart
Failure and patients with scarred or
ischemic (dead) heart tissue caused by
or related to heart attack
Program Status
Clearance from FDA to Proceed with
Phase II Clinical Trials in the U.S.
Charlestown, MA GMP Facility
12
13. Myoblast Program: Clinical Trial Summary
Phase 1
LVAD
Phase 1
CABG
Phase 1b
CABG
Phase 1b
Catheter
Patients 6 patients 12 patients 12 patients
23 Patients
(12 treated,
11 control)
Indication
LVAD Bridge
to Transplant
+CABG +CABG Catheter Injection
Dose
Single Dose -
300 MM Cells
Escalating –
10, 30, 100 and
300 MM Cells
Single Dose -
300 MM Cells
Escalating -
30, 100, 300 and
600 MM Cells
Primary
Endpoint
Safety Safety Safety Safety
Result
Demonstrated
cell survival in
humans
Dose
escalation, Safe
at all doses
Survival of cells
(cardiac
imaging),
improved
symptoms and
function
Safe at all doses,
improved
symptoms and
function
13
14. Myoblast Program: Phase II Clinical Trial
80 total patients (1:1 treatment vs. control)
Double-blind, placebo-controlled (sham procedure)
Catheter delivery of cells: percutaneous targeted delivery
Three-month, six-month, and 12-month follow-up
Endpoints: Improvement in HF symptoms and Ventricular
Volumes
Primary endpoint: Improvement in heart failure symptoms
measured by “Kansas City Cardiomyopathy Questionnaire”
Supporting endpoints: Ventricular volumes, Six minute walk test
Interim data analysis at six-months by Independent Review Board
14
15. Hemangioblast Program: Partnership
• Joint Venture with leading Korean stem cell
developer CHA Biotech Co.
• The J.V., „Stem Cell & Regenerative Medicine
International‟ (SCRMI) is focused on the
development of human blood cells and related
products
15
• Developing IND submission for red
blood cells and/or platelets derived
from iPS cells
18. The Advanced Cell Technology Team
World Class Scientific Team Led By
Seasoned Management Team
Dr. Robert Lanza, M.D. – Chief Scientific Officer
Dr. Jonathan Dinsmore, Ph.D. – Myoblast Project Advisor
Matthew Vincent, Ph.D. – Business Development and IP Strategy
18
William M. Caldwell IV – Chairman & CEO
Edmund Mickunas – Vice President of Regulatory
Roger Gay, PhD – Senior Director of Manufacturing
Rita Parker – Director of Operations
Bill Douglass – Director of Corporate Communications & Social Media
19. Thank you for your time
For more information, visit www.advancedcell.com
Advanced Cell Technology is traded on the OTC BB, symbol: ACTC